Pharsight

Opsumit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Sep, 2026

(2 years from now)

US9265762 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
May, 2027

(3 years from now)

US8367685 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Oct, 2028

(5 years from now)

US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Apr, 2029

(5 years from now)

Opsumit is owned by Actelion.

Opsumit contains Macitentan.

Opsumit has a total of 5 drug patents out of which 0 drug patents have expired.

Opsumit was authorised for market use on 18 October, 2013.

Opsumit is available in tablet;oral dosage forms.

Opsumit can be used as method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition, method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition, method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties.

The generics of Opsumit are possible to be released after 18 April, 2029.

Drugs and Companies using MACITENTAN ingredient

Market Authorisation Date: 18 October, 2013

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of s...

Dosage: TABLET;ORAL

How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage

OPSUMIT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic